Is Synmosa Biopharma stock a buy?
What Is The Conclusion?
Right now our advanced algorithms say:
Do the analyst corps agree?
Interesting Questions and Easy Answers!
Yes, Synmosa Biopharma pays dividends. Last time was Friday 13th of September 2024 where the investors holding the stock on Friday 9th of August 2024 were paid TWD0.661 per share. Over the last 15 times between 2008 and 2024, Synmosa Biopharma has paid TWD2.865681 with an average of TWD0.19 per share.
Sorry, we do not have any analyst data for this ticker
We cannot find data for Synmosa Biopharma 10 years ago, but if you had invested on Friday 22nd of November 2019 when the price was TWD15.18, you would have made a profit of TWD19.72 per share or 129.91%
Yes, the average daily trading liquidity for Synmosa Biopharma is TWD653 800 thousand. You should therefore be able to get in and out of your positions relatively fast.
Synmosa Biopharma has a normal ratio of the business financed by loans. This puts the company at some risk in periods of high inflation where borrowing costs usually go up. With a normal cash flow to debt ratio of 0.29, the company's ability to pay off the debt is normal. Synmosa Biopharma has a good net profit margin of 13.36% and should have high tolerances against inflation.
We have calculated the inflation risk for Synmosa Biopharma to be low [0.4 of 1]
US inflation for August 2024 was 0.19%. Over the last 12 months, the US inflation is 2.59%. The 10-year treasury yield that indicates the future interest level is currently 4.41 and is up 0.05 over the last 30 days.